This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

EfficacyEfficacyBosulif EfficacyBFORE StudyBFORE 5-year dataBYOND StudyStudy 200Study 200 extensionSafetyDosingSupport & ResourcesSupport & ResourcesResource overviewMaterialsVideosPatient SupportGuidelinesCML Digital ChecklistCML Patient Case StudiesCML Monitoring Video Series CML: A Cardio-Oncology PerspectiveNew Challenges Video

The content of this website has been produced in line with the BOSULIF® (bosutinib) Summary of Product Characteristics for Great Britain and Northern Ireland. For BOSULIF® (bosutinib) Prescribing Information Click here. Adverse event reporting information can be found at the bottom of the page.

CML: A Cardio-Oncology Perspective

Speaker: Professor Charlotte Manisty, Professor of Cardiology at the University College London and Cardio-Oncology Service Lead at the Barts Heart Centre.

Summary: In this short video series, Professor Charlotte Manisty discusses the practical management considerations for patients with CML and provides an overview of the European Society of Cardiology guidelines for risk stratification and management of patient with CML.

Chapter 1 - Management considerations case study
Duration: 4 minutes 10 seconds 
Chapter 2 - Management considerations CML and cardiovascular risk
Duration: 5 minutes 4 seconds 
Chapter 3 - Management considerations CV toxicities associated with TKI therapies
Duration: 5 minutes 36 seconds 
Chapter 4 - Management considerations ESC guidelines 
Duration: 10 minutes 1 seconds 
Chapter 5 - Management considerations questions and answers
Duration: 2 minutes 27 seconds 
Explore moreCML Digital Checklist

Log in/register to download the CML checklist; a resource for HCPs to aid discussions with patients on disease status and wider comorbidities that could impact treatment decisions.

Access resourceLoading
CML Patient Case Studies

Available on-demand, watch Professor Mhairi Copland present two patient case studies on the management of CP CML using BOSULIF. Content recorded from CPD approved webinar 'The Evolution of CML Management in 2023'.

Watch hereLoading

BSH, British Society of Haematology; CCI, Charlson Comorbidity Index; CML, chronic myelogenous leukaemia; CP, chronic phase; ELTS, EUTOS long-term survival; MPN, myeloproliferative neoplasms; TKI, tyrosine kinase inhibitor

PP-BOS-GBR-2036. May 2024

PP-PFE-GBR-2809. March 2021

Additional Resources

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​